Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
New York, NY, May 15th, 2025 (GLOBE NEWSWIRE) — Pathos AI, (www.pathos.com), a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion....
Read More
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
New York, NY, May 8th, 2025 (GLOBE NEWSWIRE) — Pathos AI, (www.pathos.com), a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member. Huerga brings...
Read More
Pathos Signs Strategic Agreements with AstraZeneca and Tempus to Develop the Largest Multimodal Foundation Model in Oncology
CHICAGO, April 23, 2025 — Pathos AI, Inc.(www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Tempus AI, Inc. (NASDAQ: TEM), in which the companies will...
Read More
Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor
CHICAGO, Mar. 20, 2025 (GLOBE NEWSWIRE) — Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced the first patient has been dosed in the Company’s Phase 1b/2a clinical trial evaluating pocenbrodib, a CBP/p300...